WallStSmart

EMCOR Group Inc (EME)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

EMCOR Group Inc generates 451% more annual revenue ($17.75B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 7.5%. EME appears more attractively valued with a PEG of 1.08. WST earns a higher WallStSmart Score of 67/100 (B-).

EME

Buy

64

out of 100

Grade: C+

Growth: 8.7Profit: 7.0Value: 5.0Quality: 6.3
Piotroski: 5/9Altman Z: 4.41

WST

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 2.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EME.

WSTSignificantly Overvalued (-32.8%)

Margin of Safety

-32.8%

Fair Value

$185.39

Current Price

$312.55

$127.16 premium

UndervaluedFair: $185.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EME4 strengths · Avg: 9.0/10
Return on EquityProfitability
39.2%10/10

Every $100 of equity generates 39 in profit

Altman Z-ScoreHealth
4.4110/10

Safe zone — low bankruptcy risk

Revenue GrowthGrowth
19.7%8/10

19.7% revenue growth

EPS GrowthGrowth
30.0%8/10

Earnings expanding 30.0% YoY

WST4 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

EME4 concerns · Avg: 3.3/10
P/E RatioValuation
30.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.4x4/10

Trading at 11.4x book value

Profit MarginProfitability
7.5%3/10

7.5% margin — thin

Free Cash FlowQuality
$-28.15M2/10

Negative free cash flow — burning cash

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
2.892/10

Expensive relative to growth rate

P/E RatioValuation
40.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : EME

The strongest argument for EME centers on Return on Equity, Altman Z-Score, Revenue Growth. Revenue growth of 19.7% demonstrates continued momentum. PEG of 1.08 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : EME

The primary concerns for EME are P/E Ratio, Price/Book, Profit Margin.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 40.1x leaves little room for execution misses.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.15 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

WST generates stronger free cash flow (47M), providing more financial flexibility.

Monitor ENGINEERING & CONSTRUCTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (67/100 vs 64/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

EMCOR Group Inc

INDUSTRIALS · ENGINEERING & CONSTRUCTION · USA

EMCOR Group, Inc. provides electrical and mechanical installation and construction services in the United States. The company is headquartered in Norwalk, Connecticut.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?